Drug Overview
APL-130277 (Dainippon Sumitomo/Sunovion) is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist. It is being developed for the on-demand treatment of “off” periods in late-stage Parkinson’s disease. In the more advanced stages of Parkinson’s disease with prolonged levodopa use, patients begin experiencing fluctuations in levodopa levels; these can result in peak-dose dyskinesia, and in “off” periods, where patients display muscle rigidity, tremor, and bradykinesia. APL-130277’s sublingual route of administration should allow for apomorphine’s fast onset of action, and help to quickly convert a patient in an “off” state to an “on” state.
Sumitomo Dainippon, via its US subsidiary Sunovion, is responsible for the development and marketing of APL-130277 following its 2016 acquisition of Cynapsus Therapeutics, the drug’s originator. The new Drug Application for APL-130277 was submitted in March 2018, and while Sumitomo Dainippon has previously mentioned plans to pursue development in Europe and Japan, the company’s pipeline only l.APL-130277 as being developed in the US at present.
APL-130277 (Dainippon Sumitomo/Sunovion) is a sublingual film formulation of apomorphine, a non-ergoline dopamine receptor agonist. It is being developed for the on-demand treatment of “off” periods in late-stage Parkinson’s disease. In the more advanced stages of Parkinson’s disease with prolonged levodopa use, patients begin experiencing fluctuations in levodopa levels; these can result in peak-dose dyskinesia, and in “off” periods, where patients display muscle rigidity, tremor, and bradykinesia. APL-130277’s sublingual route of administration should allow for apomorphine’s fast onset of action, and help to quickly convert a patient in an “off” state to an “on” state.
Sumitomo Dainippon, via its US subsidiary Sunovion, is responsible for the development and marketing of APL-130277 following its 2016 acquisition of Cynapsus Therapeutics, the drug’s originator. The new Drug Application for APL-130277 was submitted in March 2018, and while Sumitomo Dainippon has previously mentioned plans to pursue development in Europe and Japan, the company’s pipeline only l.APL-130277 as being developed in the US at present.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES